Skip to main content
Clinical Trials/NCT02510677
NCT02510677
Completed
Not Applicable

Three-dimensional Assessment of Intraventricular Dyssynchrony Using Fast Dobutamine Gated SPECT

University Hospital, Caen1 site in 1 country21 target enrollmentJune 2013
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
University Hospital, Caen
Enrollment
21
Locations
1
Primary Endpoint
measures of dyssynchrony parameters
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The prognosis of patients with heart failure has improved due to recent breakthrough in medical treatment and cardiac resynchronization devices. However, there is no paraclinical parameter to assess response to cardiac resynchronization therapy (CRT). This is a major issue since about a third of implanted patients will not be improved by CRT. CZT SPECT allows to perform myocardial perfusion imaging in less than 4 minutes and is able to study myocardial perfusion, viability, left ventricular function, but also ventricular asynchrony.

Using low-dose dobutamine gated SPECT and CZT camera, we aimed to assess left ventricular dyssynchrony in viable segments in patients with heart failure eligible for CRT.

Registry
clinicaltrials.gov
Start Date
June 2013
End Date
January 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient with heart failure on optimal medical therapy and targeted for cardiac resynchronization therapy according to current recommendations;
  • Age over 18 years
  • Clinically stable (without hospitalization for heart failure in the last month)
  • Sinus rhythm
  • Social security insurance
  • Signed consent form

Exclusion Criteria

  • Recent history (less than 21 days) of acute coronary syndrome or unstable angina;
  • Recent history (less than 1 month) of acute heart failure;
  • Right bundle branch block;
  • Irregular heart rate;
  • Double-chamber cardiac pacemaker
  • Patients previously implanted with a single-chamber cardioverter-defibrillator must have at least 99 percent of unstimulated QRS.
  • Countraindication to dobutamine therapy;
  • Valvular heart disease, congenital heart disease, hypertrophic cardiomyopathy;
  • Significant Ventricular arrhythmias;
  • Hypertension (upper than 160/100 mmHg);

Outcomes

Primary Outcomes

measures of dyssynchrony parameters

Time Frame: baseline

The primary endpoint is reproducible quantitative measures of dyssynchrony parameters between two successive acquisitions basal (entropy, bandwidth, standard deviation phase histogram).

Study Sites (1)

Loading locations...

Similar Trials